x

Posted 12 September, 2022

TherapeuticsMD, Inc. appointed Dr. Brian Bernick as new CEO

Nasdaq:TXMD appointed new Chief Executive Officer Dr. Brian Bernick in a 8-K filed on 12 September, 2022.


  On September 6, 2022, the board of directors (the "Board") of TherapeuticsMD, Inc., a Nevada corporation (the "Company"), appointed Dr. Brian Bernick, the Company's co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company's Chief Business Officer, as the Company's Interim Co-Chief Executive Officers and co-principal executive officers.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of TherapeuticsMD, Inc.
Health Care/Life Sciences • Pharmaceuticals
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Market Cap
$27.9M
View Company Details
TherapeuticsMD, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On September 6, 2022, the board of directors (the "Board") of TherapeuticsMD, Inc., a Nevada corporation (the "Company"), appointed Dr. Brian Bernick, the Company's co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company's Chief Business Officer, as the Company's Interim Co-Chief Executive Officers and co-principal executive officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. 

Also on September 6, 2022, the Board appointed The Honorable Tommy Thompson, who previously served as the Company's Chairman of the Board, as the Executive Chairman of the Board. 

The information regarding Dr. Bernick and Mr. Glickman required by Items 401(b), (d) and (e) of Regulation S-K is set forth in the Company's Amendment No. 1 to its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on April 29, 2022, and such information is incorporated herein by reference. Other than as described in this Current Report on Form 8-K, since the beginning of the Company's last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which either Dr. Bernick or Mr. Glickman had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000. 

Mr. O'Dowd's separation as the Company's Chief Executive Officer is a termination without "Good Cause," as defined in that certain employment agreement, dated August 3, 2021, by and between Mr. O'Dowd and the Company, and Mr. O'Dowd is entitled to receive the separation benefits provided therein upon his execution of a general release of all claims against the Company and its affiliates. In connection with his separation as the Company's Chief Executive Officer, Mr. O'Dowd ceased to serve as a member of the Board, effective on September 6, 2022.